HeartBeam Inc. (NASDAQ: BEAT) has recently been issued two new U.S. patents, further cementing its role in the advancement of cardiac care technology. These patents cover the company's compact, cable-free 3D ECG device and a rhythm analysis algorithm designed to detect arrhythmias through continuous signal input. This development is pivotal as it enhances the company's intellectual property portfolio and supports its mission to revolutionize remote cardiac diagnostics.
The 3D ECG device, notable for its use of chest and finger electrodes to capture high-fidelity signals in three non-coplanar directions, is tailored for on-demand symptom recording and 12-lead ECG synthesis. Currently under FDA review, the device's software is backed by data from the VALID-ECG pivotal study, promising a new era of precision in cardiac diagnostics. The rhythm algorithm, compatible with various cardiac monitoring systems, improves diagnostic accuracy by initiating targeted data collection upon detecting abnormal rhythms.
With a total of 20 issued patents and 34 additional filings, HeartBeam is at the forefront of digital cardiac care innovation. The company's future plans include integrating AI capabilities to further enhance diagnostic accuracy, underscoring its commitment to transforming cardiac health management. This advancement is not just a milestone for HeartBeam but also a beacon of hope for patients worldwide, offering the potential for timely and accurate cardiac diagnostics outside traditional medical facilities.
